Inhibition of PI3K/AKT pathway with a specific inhibitor (LY294002) has been proposed to reduce multi-drug resistance mediated by ABCG2 in cancer stem-like cells and improve GBM chemosensitivity [74]. Here, AKT1 is linked to cancer.